| __timestamp | Bristol-Myers Squibb Company | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 34916000 |
| Thursday, January 1, 2015 | 5001000000 | 36949000 |
| Friday, January 1, 2016 | 5002000000 | 45240000 |
| Sunday, January 1, 2017 | 4849000000 | 62416000 |
| Monday, January 1, 2018 | 4551000000 | 81289000 |
| Tuesday, January 1, 2019 | 4871000000 | 100359000 |
| Wednesday, January 1, 2020 | 7661000000 | 105326000 |
| Friday, January 1, 2021 | 7690000000 | 122356000 |
| Saturday, January 1, 2022 | 7814000000 | 152848000 |
| Sunday, January 1, 2023 | 7772000000 | 184259000 |
| Monday, January 1, 2024 | 8414000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Bristol-Myers Squibb Company, a leader in the sector, has consistently demonstrated robust spending on Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, their SG&A expenses grew by approximately 36%, peaking in 2022. This reflects their aggressive market strategies and commitment to maintaining a competitive edge.
In contrast, Corcept Therapeutics Incorporated, a smaller player, has shown a remarkable increase in SG&A spending, with a staggering 428% rise over the same period. This surge underscores their strategic investments in growth and market penetration.
The juxtaposition of these two companies highlights the diverse approaches within the pharmaceutical industry, where size and strategy dictate financial priorities. As the market continues to evolve, these spending patterns offer a glimpse into the future trajectories of these companies.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights